Enabling Regenerative Therapies without Immunosuppression

Episode Summary

Executive Summary: The interview explores iTolerance’s strategy to enable regenerative cell and organ therapies without lifelong immunosuppression, focusing on type 1 diabetes first. CEO Anthony Jappour explains the company’s ITOL 100 immune-tolerance platform and ITOL 102 cell therapy, outlines encouraging preclinical results, and describes a global regulatory path and additional liver-failure program.

Main Topics: Type 1 diabetes burden and unmet need (Priority: 5/5): Jappour explains type 1 diabetes as an inability to produce insulin, leading to chronic hyperglycemia and dangerous complications. He stresses that current care is burdensome, imperfect, and life-altering for patients and families. Limits of islet transplantation today (Priority: 5/5): The conversation reviews why islet transplantation has not become routine in the U.S.: donor scarcity, FDA treatment of cadaveric islets, and the need for lifelong immunosuppression that harms both patients and grafts. ITOL 100 immune-tolerance platform (Priority: 5/5): iTolerance’s core technology is a microgel plus FAS-L fusion protein designed to kill incoming hostile T cells locally at the transplant site, creating localized immune tolerance without suppressing the whole body. ITOL 102 for type 1 diabetes (Priority: 5/5): ITOL 102 combines ITOL 100 with stem-cell-derived insulin-producing cells. Early preclinical work in diabetic mice and monkeys suggests durable graft function and possible involvement of regulatory T cells. Regulatory and development strategy (Priority: 4/5): Jappour outlines a staged path: further preclinical work, FDA interactive meeting, pre-IND discussions, IND-enabling studies, and eventual clinical trials, with parallel pursuit of global markets. Expansion beyond diabetes (Priority: 4/5): The platform is also being applied to liver failure via ITOL 201 and a collaboration with Ligenesis, with broader interest in using ITOL 100 across other tissue and cell therapies.

Key Arguments: Type 1 diabetes remains inadequately managed because insulin therapy requires constant monitoring and still exposes patients to severe hypo- and hyperglycemic risk. Islet transplantation is scientifically promising but constrained in the U.S. by regulatory status, donor scarcity, and the toxicity of lifelong immunosuppressive drugs. ITOL 100 aims to create local immune tolerance at the graft site, avoiding systemic immunosuppression while preserving the rest of the immune system. Combining ITOL 100 with stem-cell-derived insulin-producing cells could make a scalable curative approach for type 1 diabetes. Preclinical animal data support the concept of longer-lasting engraftment, though durability in humans remains unproven. The company is prioritizing type 1 diabetes while keeping the platform open to other regenerative medicine applications. Partnerships with highly specialized academic centers are essential because transplantation expertise is concentrated in institutions like the Diabetes Research Institute and the University of Pittsburgh ecosystem.

Data Points: Age-related life-shortened lifespan: Up to 2 decades - Jappour says people diagnosed with type 1 diabetes before age 10 can lose up to 20 years of life. Preclinical graft durability: 6 months - Allogeneic islet grafts in diabetic animal studies were maintained for six months. Monkey study duration: 180 days - The monkey study was stopped at 180 days due to the COVID pandemic, not because grafts failed. Rapamycin exposure window: 15 to 90 days - Animal studies used a limited rapamycin course to help expand T-regulatory cells. FDA follow-up meeting step: Interactive meeting - Planned early regulatory discussion after generating preclinical data for ITOL 102. Expected start after IND filing: Within 30 days - Jappour notes clinical studies can typically begin about 30 days after an IND is filed if FDA discussions are clear. Liver program timeline: No sooner than the end of 2025 - Estimated earliest timing for clinical entry of the ITOL 201 liver-failure program.

Pivotal Quotes: "Removing the need for lifelong immune suppression in pancreatic glandular transplantation is truly the holy grail for this field of medicine." — Anthony Jappour: Explaining the significance of ITOL 100's mechanism in transplant tolerance. "Type 1 diabetes is a 24-7 disease, and the patients never get a break." — Anthony Jappour: Describing the burden and constant management required by current care. "We do know that if we can get rid of the immunosuppression, that we do think that the islets will have a greater chance of surviving." — Anthony Jappour: Discussing the rationale for combining immune tolerance with transplanted cells.

Implications: If iTolerance’s localized immune-tolerance approach works in humans, it could materially improve durability and scalability of cell and organ therapies while avoiding systemic immunosuppression. The first major test is whether ITOL 102 can translate strong animal data into a human cure path for type 1 diabetes.